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Neurologic conditions including stroke, Alzheimer disease, Parkinson disease, and Huntington disease
are leading causes of death and long-term disability in the United States, and efforts to develop novel
therapeutics for these conditions have historically had poor success in translating from bench to
bedside. Hypoxia-inducible factor (HIF)-1a mediates a broad, evolutionarily conserved, endogenous
adaptive program to hypoxia, and manipulation of components of the HIF pathway is neuroprotective
in a number of human neurological diseases and experimental models. In this review, we discuss
molecular components of one aspect of hypoxic adaptation in detail and provide perspective on which
targets within this pathway seem to be ripest for preventing and repairing neurodegeneration. Further,
we highlight the role of HIF prolyl hydroxylases as emerging targets for the salutary effects of metal
chelators on ferroptosis in vitro as well in animal models of neurological diseases.
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Over the past 20 years, our laboratory has used two primary
approaches to understand therapeutic strategies for preventing
oxidative stress-mediated neurodegeneration. First, we have studied
the endogenous mechanisms that lead to or prevent cell death
induced by depletion of the antioxidant glutathione in primary
neurons in vitro. Detailed biochemical analysis of this form of death,
recently termed ferroptosis [1], has revealed novel redox-regulated
transcriptional pathways that can compensate for persistent glu-
tathione depletion and oxidative stress to foster cell survival [2,3].
In parallel, investigations into the mechanism of classical ‘‘antiox-
idants’’ in our in vitro model have surprisingly revealed remarkable
and recurrent bias toward transcriptional adaptive mechanisms often
involving more than 100 genes [4–7]. In this review, we discuss
evidence from these distinct investigations and how that evidence
has led us to focus our attention on an evolutionarily conserved
adaptive response and its role in neuroprotection.Fig. 1. Schematic of oxygen-dependent HIF-1a regulation. (A) Under normoxic
conditions, PHDs hydroxylate P564 on HIF-1a, allowing it to be recognized by the
E3 ubiquitin ligase von Hippel-Lindau protein (VHL), ubiquitinated, and targeted
for proteasomal degradation. As members of a large family of iron- and 2-oxoglu-
tarate-dependent dioxygenases, PHDs integrate multiple signals of metabolic
homeostasis and are one of many such sensors; further, PHDs have HIF-indepen-
dent substrates, and HIF protein levels and transcriptional activity are regulated in
many PHD-independent ways. (B) Under hypoxia, PHDs are inhibited, allowing
HIF-1a to elude degradation, dimerize with its b partner in the nucleus, bind
transcriptional coactivators and hypoxia-response elements in promoter regions
of target genes, and enhance transcription rates. Glucose deprivation has been
reported to decrease hypoxic stabilization of HIF-1a; the mechanisms by which
this occurs are unclear.Oxygen-dependent metabolism
It is thought that self-replicating RNA became enclosed in a
phospholipid membrane about 3.8 billion years ago, forming the
basic unit of life called the cell (reviewed by [8]). These cells were
able to obtain the energy required to replicate themselves and
perform other necessary tasks from the sea of organic molecules
from which they originated. However, such a self-limiting situa-
tion drove cells to evolve mechanisms through which they could
autonomously generate, store, and use energy.
The principal pathways of energy metabolism are remarkably
similar in all present-day cells, indicating that they emerged early
in the process of evolution and have been conserved. For instance,
all cells use ATP as the currency of energy to drive the synthesis of
cell constituents and to carry out other energy-requiring activ-
ities. The mechanisms by which cells generate ATP are thought to
have evolved sequentially: ﬁrst glycolysis, then photosynthesis,
and ﬁnally oxidative metabolism. In glycolysis, glucose is broken
down to produce 2 ATP molecules. In photosynthesis, energy from
the sun is harvested to produce glucose, which creates molecular
oxygen (O2) as a by-product and has caused that oxygen to
become abundant in the earth’s atmosphere. In oxidative meta-
bolism, oxygen is used to break down glucose much more
efﬁciently than in glycolysis, yielding 36 ATP molecules instead
of 2.
Because of this efﬁciency, almost all present-day cells—including
archaea, bacteria, and eukaryotic cells in humans—use oxidative
reactions as their principal source of energy. For cells to rely on
oxygen for metabolism, they need to be able to sense a decrease in
oxygen availability—a phenomenon called hypoxia—and to then
trigger a response program that helps them to cope with that
decrease. One simple way to do so is to have sensor enzymes that
use oxygen to inhibit the response program; when oxygen supply
drops, the sensors are inhibited and the response program is then
rapidly activated.
Cells as simple as bacteria express prolyl 4-hydroxylase domain-
containing enzymes (PHDs) that use oxygen to add a hydroxyl group
to proline residues on speciﬁc substrate proteins. This hydroxylation
is a highly evolutionarily conserved sensory mechanism for oxygen;in fact, prolyl 4-hydroxylation is the single most prevalent posttran-
slational modiﬁcation in humans [9]. In all animal cells, even those of
the simplex animal, Trichoplax adhaerens, one of the proteins subject
to prolyl 4-hydroxylation is called hypoxia-inducible factor (HIF) [10].Hypoxia-inducible factor
HIF was ﬁrst identiﬁed as a transcriptional activator that binds
to the hypoxia-response element (HRE) in the promoter region of
erythropoietin and has since been shown to coordinate many
evolutionarily conserved adaptive responses to hypoxia [11]. HIF
target genes include VEGF, EPO, GLUT1, PFK1, BNIP3, neuroglobin,
and dozens of other genes that work in concert at cellular, local
tissue, and systemic levels, to restore oxygen delivery, to enhance
glucose uptake and glycolysis, to reduce mitochondrial content
and the rate of oxidative phosphorylation, and to regulate cell
survival either by promoting adaptation or by engaging pro-
grammed cell death under prolonged or severe stress conditions.
HIF-1 regulates gene expression not only by direct binding to
target gene promoters at the consensus sequence (50-RCGTG-30),
but also by counting among its targets numerous transcription
factors, histone demethylases, and microRNAs that can in turn
affect gene expression [69].
HIF is a heterodimer consisting of a constitutively present b
subunit and a short-lived, oxygen-regulated a subunit. HIF family
members are diagrammed in Fig. 1. Three a isoforms have been
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served, sharing approximately 90% homology with mouse and rat.
All a and b subunits contain an N-terminus basic helix–loop–
helix domain for DNA binding and a Per-ARNT-Sim (PAS) domain
for dimerization. HIF-1a and -2a subunits contain two oxygen-
dependent degradation domains and a C-terminal transactivation
domain (C-TAD) that binds the coactivators CBP/p300; HIF-3a is
truncated to lack the C-TAD and thus is speculated to act as a
competitive inhibitor of HIF-1a and HIF-2a.
HIF subunits do not only activate transcription of HRE-
regulated genes, though. HIF-2a was recently shown to bind the
RNA-binding protein RBM4 and the cap-binding eIF4E2 to initiate
translation of select mRNAs; this process occurs under conditions
of hypoxia in which the normal cap-dependent translation
machinery is inhibited [12]. HIF-1a binds to the transcription
factor Sp1 to block activation of the gene encoding the mismatch
DNA repair protein MSH2 and also binds to the Notch intracel-
lular domain to potentiate transcriptional activation of Notch
target genes [69]. HIF-b subunits, ﬁrst identiﬁed as the aryl
hydrocarbon receptor nuclear translocator, are necessary for the
xenobiotic response mediated by the aryl hydrocarbon receptor.
HIF-1a is the most widely studied of the a isoforms and is
expressed in all human cell types, whereas HIF-2a shows more
restricted expression. Both HIF-1a and HIF-2a show some selec-
tivity in their cassettes of target genes. For example, HIF-1a
preferentially induces glycolytic enzyme genes, whereas HIF-2a
induces several genes involved in neurological disorders and
cancer invasion [13]. HIF-1a appears to mediate acute responses
to hypoxia, whereas HIF-2a is activated primarily during chronic
hypoxia.
Constitutive deletion of the Hif1a gene in mice causes lethality
by day 11 of embryonic development, resulting from cardiovas-
cular malformation and defective cephalic vascularization, indi-
cating that HIF-1a is essential for embryonic vascularization.
Neural-cell-speciﬁc HIF-1a-deﬁcient mice exhibit hydrocephalus
accompanied by a reduction in neural cells and an impairment of
spatial memory, indicating that expression of HIF-1a in neural
cells is essential for normal development of the brain.Oxygen-dependent degradation of HIF-1a
HIF-a protein half-life is regulated by oxygen-dependent
degradation (Fig. 1A). Under normoxic conditions, PHDs hydro-
xylate P564 on HIF-1a, allowing the domain to be recognized by
Von Hippel-Lindau (VHL) protein, an E3 ubiquitin ligase, and
thereby targeted for degradation by the 26s proteasome [14–16].
Under hypoxia, a decrease in PHD activity leads to HIF-1a
accumulation, heterodimerization with b subunits, recruitment
of the histone acetyltransferases p300 and CBP, and transactiva-
tion of target gene expression [17].
A number of other proteins contribute to the canonical PHD–
VHL–proteasome degradative pathway. ARD1 acetylates
lysine532 of HIF-1a, located in the oxygen-dependent degrada-
tion (ODD) domain. This modiﬁcation appears to enhance recruit-
ment of VHL, but is not required for HIF-1a degradation under
normal conditions [18]. VHL binds hydroxylated PHD in complex
with elongin B, elongin C, Cul2, and Rbx1, all of which are
required for ubiquitination [19].HIF PHDs
PHD enzymes are highly conserved, iron-dependent, 2-
oxoglutarate-dependent dioxygenases. PHDs are the primary
oxygen sensors that keep HIF-1a protein levels low duringnormoxia and allow the protein to be rapidly stabilized upon
hypoxia [15,16]. Pharmacological and molecular studies have
demonstrated that PHD inhibition is broadly neuroprotective
and mediates the salutary effects of iron-chelating drugs. FDA-
approved drugs that inhibit PHDs have been identiﬁed and are
poised for clinical trials [20,78,111].
PHDs, also known as Egl 9 homologs (EGLNs), exist in three
isoforms named PHD1 (EGLN2), PHD2 (EGLN1), and PHD3
(EGLN3). They are part of a superfamily of iron-dependent,
2-oxoglutarate-dependent dioxygenases; other members of this
family include the collagen prolyl hydroxylases, which regulate
the extracellular matrix, and the jumonji-domain-containing
histone demethylases, which regulate gene expression through
chromatin structure modiﬁcations. PHDs hydroxylate both P564
and P402 on HIF-1a, but under conditions of normoxia, P564 is
hydroxylated before P402 and primarily regulates oxygen-
dependent degradation [21]. PHD2 is the most abundant PHD
and the most important in setting steady-state levels of HIF-1a
subunits [22]. PHDs, especially PHD2 and PHD3, are transcrip-
tionally upregulated by HIF-1 and are therefore important not
only for basal regulation of HIF but also for feedback inhibition
during prolonged hypoxia or rapid degradation upon reoxygena-
tion [23]. Although all three PHD isoforms recognize the LXXLAP
motif, they show some isoform-selective preferences for ﬂanking
regions on substrates, which provides some direction for attempts
to develop isoform-speciﬁc inhibitors [24].
Several isoform-speciﬁc, HIF-independent functions of the
PHDs have been identiﬁed. Some alternative substrates have been
identiﬁed that show selectivity among the PHD isoforms. The b2-
adrenergic receptor, a G-protein-coupled receptor important for
cardiac function, is hydroxylated speciﬁcally by PHD3, ubiquiti-
nated by VHL, and proteasomally degraded under hypoxia [25].
Rbp1, the large and enzymatically active subunit of RNA poly-
merase II, is recruited to DNA under oxidative stress conditions in
a manner requiring its hydroxylation at Pro1465 and subsequent
nondegradative ubiquitination by VHL; PHD1 is necessary for
Pro1465 hydroxylation, whereas PHD2 inhibits this hydroxylation
[26]. PHD1 also speciﬁcally regulates cyclin D1 in a hydroxylase-
dependent, transcription-dependent, HIF-independent manner:
PHD1 inactivation decreases cyclin D1 levels and suppresses mam-
mary gland cell proliferation and tumor formation in vivo [27].
Indeed, PHDs are not only gatekeepers for the oxygen-dependent
degradation of HIF-1a, but are also integrated sensors of cellular
metabolism [28]. Proline hydroxylation is enzymatically coupled
to the decarboxylation of 2-oxoglutarate (2-OG), a process that
yields succinate and CO2. PHD activity therefore requires 2-OG
and is inhibited in the presence of high concentrations of
tricarboxylic acid cycle intermediates such as pyruvate, isocitrate,
oxaloacetate, succinate, or fumarate. Because PHD enzyme activ-
ity also requires iron, PHDs serve moreover as sensors of iron
homeostasis [29].
Although it is well established that PHDs, particularly PHD2,
are critical for normoxic degradation of HIF-1a, it remains
debated exactly how hypoxia inhibits PHD activity. At least three
distinct models have been proposed to explain this phenomenon.
The ﬁrst model proposes that PHD enzymatic activity could be
reduced as substrate levels drop; this is a simple model in which
PHDs are the primary oxygen sensors regulating HIF and is
consistent with Km for PHD observed in vitro [30]. The second
model argues that O2 consumption by an intact electron transport
chain redistributes O2 intracellularly into mitochondria [31,32].
Models 1 and 2 are not mutually exclusive, however, because
subcellular O2 gradients could shift the apparent Km of PHDs for
O2 in vivo. The third model purports that mitochondrial peroxide
production increases under hypoxia and that H2O2 dismutated
from O2
 produced at Reiske proteins is a speciﬁc signaling
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by several groups suggests that the stabilization of HIF-1a by
hypoxia requires signaling through mitochondria and intracellu-
lar kinases, in contrast to HIF-1a stabilization by anoxia or by
PHD-inhibiting iron chelators [33,34]. Models 2 and 3 invoke
conﬂicting data on whether mitochondrial reactive oxygen
species (ROS) production is necessary for or irrelevant to hypoxic
HIF stabilization.Von Hippel-Lindau protein
VHL was ﬁrst identiﬁed as a tumor-suppressor gene that is
mutated in Von Hippel-Lindau syndrome, a dominantly inherited
familial cancer syndrome that precipitates a variety of malignant
and benign tumors. The most common of these tumors are central
nervous system hemangioblastomas (benign, highly vascularized
tumors), pheochromocytomas (tumors originating from the chro-
mafﬁn cells of the adrenal glands), and clear-cell renal-cell
carcinomas (ccRCCs). Somatic mutations affecting VHL are also
seen in the majority of cases of sporadic ccRCC.
VHL was shown to mediate HIF-1a degradation, which explains
the angiogenic phenotype of many VHL-null tumors [35]. VHL
was subsequently shown to have a number of substrates other
than HIF-a, including ﬁbronectin and collagen IV a2 chain in the
extracellular matrix, microtubules, the RNA polymerase II sub-
units Rbp1 and Rbp7, atypical protein kinase Cl, VHL-interacting
deubiquitinating enzymes VDU-1 and VDU-2, p27, p53, and Jade-1
[36]. VHL-mediated ubiquitination does not always lead to sub-
strate degradation, though; VHL stabilizes p53 and Jade-1, for
example [37].The ubiquitin–proteasome degradation pathway
An ATP-dependent proteolytic system independent of lyso-
somes was ﬁrst described in reticulocytes [38], and the Nobel
Prize in Chemistry 2004 was awarded jointly to Aaron Ciechan-
over, Avram Hershko, and Irwin Rose for the discovery of
ubiquitin-mediated protein degradation.
Proteins are targeted for proteasomal degradation by the
covalent addition of at least four ubiquitin molecules to a lysine
residue on the client protein [39]. The addition of ubiquitin
requires three enzymatic steps. First, a ubiquitin-activating
enzyme (E1) couples the hydrolysis of ATP with adenylylation
of a ubiquitin molecule [40]. This adenylylated ubiquitin is then
transferred to a cysteine of a second enzyme, ubiquitin-
conjugating enzyme (E2). Finally, a ubiquitin ligase (E3) recog-
nizes the speciﬁc protein to be ubiquitinated and transfers the
ubiquitin from E2 to the target protein. Addition of further
ubiquitin groups can be mediated by an E3 or an E4 polyubiquitin
chain conjugation factor. This conjugation is signiﬁcant, because
the way in which ubiquitin chains are constructed can determine
the fate of ubiquitinated proteins [41]. Polyubiquitinated proteins
are recognized by the 19S regulatory cap, then deubiquitinated
and unfolded, so that they can be translocated through a narrow
gate into the central channel of the 20S catalytic core of the
proteasome. The b subunits of the 20S core act as proteases to
degrade client proteins, releasing short peptides typically 7–9
amino acids in length.
ATP is required at several steps of the ubiquitin–proteasome
degradative pathway (reviewed by [42]). First, ATP hydrolysis is
required for activation of ubiquitin by E1, but not for later steps of
ubiquitin conjugation. ATP binding, but not hydrolysis, is required
for the assembly of the 26S proteasome from the 19S and 20S
particles, as well as for target protein binding by the 19S subunit,gate opening, translocation, and proteolysis. ATP hydrolysis is
required for the unfolding of substrate proteins and, in some cases
but not all, for proteolysis and deubiquitination [43,44].
ATP is required for proteasomal degradation and can also be
depleted under conditions of ischemia (when blood supply drops,
leading to a scarcity of oxygen, glucose, and other energy substrates).
Nevertheless, it is worth noting that proteasomal degradation
continues during brief ischemia and can even mediate rapid
preconditioning tolerance to later harmful ischemia [45]. In
contrast, prolonged ischemia can inactivate proteasomal degra-
dation, leading to the accumulation of ubiquitinated proteins.
Such accumulation may contribute to cell stress or form aggre-
gates that may in turn be degraded by the autophagosome/
lysosome pathway [45]. A major regulator of ATP homeostasis,
AMPK, is negatively regulated by the proteasome such that
inhibition of proteasomal degradation can stimulate the energy
conservation program mediated by AMPK [46].Regulation of HIF-1a by ODD-independent mechanisms
HIF-1a synthesis, stability, and ability to activate target gene
transcription can be regulated through many known ODD-
independent mechanisms under various physiological and patho-
logical conditions.
Regulation of HIF-1a activity
Once HIF-1a is stabilized, its ability to bind p300/CBP is
negatively regulated by an O2
 and Fe2
þ-dependent asparaginyl
hydroxylase, a factor inhibiting HIF, which targets Asn803 within
the C-TAD [47]. In addition to CPB and p300, other histone
acetyltransferases (HATs) that coactivate transcription have been
shown to interact with and potentiate HIF, including SRC1 and
TIF2. On the other hand, the HAT CITED2 competes with HIF-1 for
binding to p300/CBP and is transcriptionally upregulated in
hypoxia by HIF-1, and thus may provide a negative feedback on
HIF-1 activity during extended hypoxia [48]. CITED2 is also a
negative regulator of NF-kB-mediated gene transcription and
thus may serve a general role in feedback regulation for homeo-
static programs.
HIF-1a phosphorylation by casein kinase 1d at Ser247 within
the PAS domain inhibits dimerization with HIF-1b and subse-
quent transcriptional activity, without affecting HIF-1a stability
or nuclear accumulation [49]. HIF-1a is phosphorylated by p42/
p44 mitogen-activated protein kinases (MAPKs 1/3) at Ser641/
643, and this phosphorylation enhances HIF-1-dependent nuclear
localization and gene transcription [50,51]. The regulatory-
associated protein of mTOR (raptor) interacts with HIF-1a at a
mammalian target of rapamycin (mTOR) signaling motif located
in the N-terminus of HIF-1a. Raptor facilitates binding of HIF-1a
to the coactivator CBP/p300, thus enhancing HIF-1a-mediated
transcription [52]. S-nitrosylation of Cys800 and the redox-
responsive protein Ref-1/APE-1 also promote HIF-1 transcrip-
tional activity in a manner dependent on p300 [53–55].
ODD-independent regulation of HIF-1a protein stability
The half-life of HIF-1a is regulated in an O2-independent
manner by the competitive binding of either the heat shock
protein 90 (HSP90) or the receptor of activated protein kinase C
(RACK1) to the PAS domain of HIF-1a. RACK1 is an E3 ubiquitin
ligase that interacts with elongin C via a binding site that shows
signiﬁcant sequence similarity to VHL, thereby promoting HIF-1a
ubiquitination and degradation in a manner that is independent
of PHD2 and VHL [56]. RACK1-mediated HIF-1a degradation can
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activated phosphatase that dephosphorylates RACK1, thus block-
ing its dimerization and binding to elongin C, suggesting that
HIF-1a can be stabilized by increases in intracellular calcium [57].
GSK3 can directly phosphorylate Ser551, Thr555, and Ser589
within the ODD domain, leading to recognition by a ubiquitin
ligase called F-box and WD protein and targeting HIF-1a for
proteasomal degradation independent of prolyl hydroxylation
and VHL binding [58,59]. HIF-associated factor, an E3 ligase for
HIF-1a (but not HIF-2a), plays an important role in oxygen-
independent HIF-1a regulation in cancer by degrading HIF-1a in
response to growth factor signaling, and perhaps other stimuli,
even in the presence of hypoxia [60]. The small ubiquitin-related
modiﬁer (SUMO) can be conjugated to HIF-1a at Lys391 and
Lys477 and enhance HIF-1a stability [61], but the mechanism by
which this stabilization occurs and the physiological or pathological
context in which SUMOylation regulates HIF-1 have not been
determined. In response to oxidative stress, a small ubiquitin-like
protein called neural precursor cell expressed developmentally
downregulated 8 (NEDD8) becomes conjugated to the PAS domain
of HIF-1a and stabilizes HIF-1a [109]. The role of ROS in hypoxic
HIF-1a stabilization is controversial.
Regulation of HIF-1a transcription and translation
HIF-1a is regulated by positive and negative feedback loops;
in addition to hypoxic induction of PHD3 described above, Hif1a
itself is among the target genes of HIF-1a. Hypoxic induction of
HIF-1a mRNA requires the activity of the PI3K/Akt pathway but
not the ERK1/2 pathway [62].
NF-kB, a major mediator of immune responses, binds to the
promoter of HIF-1a and increases HIF-1a mRNA levels under
hypoxia [62]. Cross-talk between NF-kB and HIF-1a is complex;
for example, NF-kB has long been known to be induced by
hypoxia [63], and more recently it was shown that NF-kB protein
levels are increased under hypoxia downstream of HIF PHD1
hydroxylation of IKKb [64].
The NO donors NOC18 and S-nitrosoglutathione induce HIF-1a
expression and transcriptional activity without inhibiting HIF-1a
hydroxylation, ubiquitination, and degradation, indicating an
effect on HIF-1a protein synthesis that was conﬁrmed by pulse
labeling studies and shown to require PI3K and MAPK signaling
through the translational regulatory proteins eukaryotic transla-
tion initiation factor 4E-binding protein (4E-BP1), p70 S6 kinase,
and eIF-4E [65]. The tumor suppressor p53 binds HIF-1a and
promotes its degradation in hypoxia via Mdm-2-mediated ubi-
quitination and proteasomal degradation [66]. This can be over-
come by Jun activation domain-binding protein-1, which was
previously known as a coactivator of the AP-1 transcription factor
before it was shown to activate HIF-1 transcriptional activity by
interfering with p53 binding to HIF-1 [67].
Growth factor signaling boosts the rate of translation of HIF-1a
and a select group of other mRNAs (reviewed by [68]). Receptor
tyrosine kinases in the plasma membrane are activated by
extracellular growth factor ligand binding, which initiates two
parallel cascades of phosphorylation activation: PI3K-Akt/PKB-
mTOR and RAS-MEK-ERK. mTOR and ERK converge on two
mechanisms of promoting translation: activation of S6K and
subsequent activation of the ribosomal protein S6, as well as
inhibition of 4E-BP1, to disinhibit cap-dependent translation
mediated by eIF-4E. Additionally, ERK activates MNK, which
directly phosphorylates eIF-4E to increase its activity. It is not
known precisely how mTOR signaling promotes the translation of
HIF-1a, but HIF-1a is likely to be particularly sensitive to
ﬂuctuations in the rate of protein synthesis because of its short
half-life (approximately 5 min) under normoxic conditions. Themany levels of regulation on HIF-1a, and its involvement in
cellular responses to stimuli other than hypoxia, such as inﬂam-
mation and growth factor signaling, all support the notion that
HIF-1a is a critical central regulator of adaptive transcriptional
responses.HIF PHD inhibition as a neuroprotective strategy
Because HIF-1a is primarily degraded under normoxia in a
manner requiring PHDs, HIF can be pharmacologically induced by
structurally diverse small-molecule PHD inhibitors. HIF PHD
inhibition consistently produces neuroprotection in diverse neu-
rological disease models, including stroke [5,69], Alzheimer dis-
ease [70,71], allergic encephalomyelitis [72], Parkinson disease
[73], oxidative stress [74], excitotoxicity [75], trophic factor
deprivation [76], and mitochondrial dysfunction [77] (Table 1).
PHDs have been identiﬁed as the critical targets of iron chelators
such as desferoxamine that are clinically beneﬁcial in many
neurological disorders and that recapitulate the neuroprotective
effects of hypoxic preconditioning on later ischemic challenge [5].
Novel PHD inhibitors poised for clinical trials have been identiﬁed
through high-throughput screening of FDA-approved drug
libraries [78]. PHD inhibition produces neuroprotection via both
HIF-dependent and HIF-independent mechanisms [79]. Thus, PHD
inhibition is a promising therapeutic approach that engages
multiple downstream effector pathways, of which HIF is one.
Prolyl hydroxylation is substantially more sensitive than
asparaginyl hydroxylation to inhibition by iron chelators [80].
Therefore, FDA-approved iron chelators or more speciﬁc PHD
inhibitors could therapeutically activate the many downstream
effectors of PHD signaling. There is also potential for off-target
effects upon pathophysiological or pharmacological HIF manip-
ulation. For these reasons, probing the mechanisms by which HIF
is regulated by ischemia and by candidate drugs is as important
for safety and efﬁcacy as measuring HIF activity itself. Identifying
the physiological, pathological, and pharmacological conditions
permissive to HIF stabilization and their mechanism of action is
an important ﬁrst step in understanding the therapeutic beneﬁts
or potential side effects of manipulating HIF signaling.HIF PHD inhibitors abrogate ferroptosis, a novel form
of nonapoptotic death
Recently a novel form of iron-dependent, nonapoptotic death
was deﬁned by Brent Stockwell and coworkers [1]. Using Ras
mutant cancer cells, the group elegantly demonstrated that
cancer cell death induced by the chemotherapeutic agent erastin
had unique morphological, biochemical, and genetic features
compared to cell death induced by the nonspeciﬁc tyrosine kinase
inhibitor staurosporine, the ROS hydrogen peroxide, or the
autophagy inducer rapamycin. Speciﬁcally, ferroptosis could be
blocked by iron chelators (deferoxamine), ERK signaling pathway
inhibitors (e.g., U0126), and cycloheximide, a protein synthesis
inhibitor. Moreover, an unbiased short interfering RNA screen
involving 1087 genes identiﬁed 6 genes that are required for
erastin-induced ferroptosis: ribosomal protein L8 (RPL8), iron-
response element binding protein 2 (IREB2), ATP synthase Fo
complex subunit C3 (ATP5G3), citrate synthase (CS), tetratricopep-
tide repeat domain 35 (TTCC35), and acetyl-CoA synthetase family
member (ACSF2) (Table 2). In this model, cell death occurs
downstream of inhibition of the plasma membrane transporter
for cystine, Xc . Inhibition of cystine transport leads to depletion
of antioxidant levels via starvation of cysteine, the rate-limiting
amino acid precursor in glutathione synthesis. Erastin thus
Table 2
Features of ferroptosis.
Characteristic feature Occurrence
Morphology Smaller mitochondria with increased membrane density
Cell death mechanism Iron-dependent ROS accumulation
Precursor requirement Requires initial lipid precursor
Possible cell death rescue mechanism Iron chelation and genetic inhibition of cellular iron uptake
Regulatory genes RPL8, IREB2, ATP5G3, CS, TTC35, ACSF2
Reported inducers RSLs such as erastin and RSL-3
Characterized inhibitor Ferrostatin-1
Other inhibitory compounds Iron chelator DFO, antioxidant Trolox, MEK inhibitor U0126, protein synthesis inhibitor
cycloheximide
Reported incidences of ferroptosis Glutamate-induced neurotoxicity and cell death of certain cancer cells
Bioenergetics failure (a necrotic feature) No
Cytoplasmic and organelle swelling (a necrotic feature) No
Plasma membrane rupture (a necrotic feature) No
Apoptotic bodies (an apoptotic feature) No
Chromatin condensation (an apoptotic feature) No
Formation of double membrane vesicle (an autophagic cell death
feature)
No
Data were taken from Ref. [1]. Ferroptosis seems to be a biochemically, morphologically, and genetically distinct form of cell death that is sensitive to iron chelation in
cancer cells. Although ferroptosis has not been characterized fully in neurons, our studies suggest that several agents known to block ferroptosis in cancer cells also block
ferroptosis in primary neurons (e.g., ERK inhibitors, cycloheximide, and iron chelators). Our studies suggest that iron chelators target the HIF prolyl hydroxylases to inhibit
ferroptosis [84,118].
Table 1
Small molecules with HIF PHD inhibitory activity are neuroprotective in a host of models of neurological conditions in vitro and in vivo.
Neurological
disease
HIF PHD inhibitor In vitro model In vivo model Ref.
Stroke Deferoxamine (DFO) Oxygen glucose deprivation (OGD) [119–121]
Glutathione depletion model [5,74,84,122]
NMDA toxicity [123,124]
Nerve growth factor (NGF) deprivation [125]
Hypoxia–ischemic injury [126]
Middle cerebral artery occlusion (MCAO) [5,98,119,127–130]
Ethyl-3,4-dihydroxy
benzoate (DHB)
Glutathione depletion model [5,84,122]
H2O2-induced oxidative injury [131]
NGF deprivation [76]
MCAO [5,98]
Dimethyl-oxalyl glycine
(DMOG)
OGD [132]
Glutathione depletion model [122]
NGF deprivation [76]
MCAO [69,132]
Parkinson
disease
DFO 6-Hydroxydopamine (6-OHDA) [133]
1-Methyl-4-phenylpyridinium (MPPþ) [99]
Rotenone [99]
6-OHDA) [134]
DHB MPPþ [79]
1-Methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)
[79,135]
DMOG MPPþ [79]
Alzheimer
disease
DFO SHSY-5Y cells overexpressing the human APP
Swedish mutation
[136]
APP/PS1 mice [136]
P301L mice [137]
Huntington
disease
DFO 3-Nitropropionic acid [77,138]
DMOG [77]
Friedreich
ataxia
DFO H2O2-induced oxidative injury in FRDA ﬁbroblasts [139]
Frataxin expression in FRDA lymphoblasts [140]
Desferoxamine inhibits HIF PHD activity by depleting iron, a critical cofactor for these and other iron-, 2-oxoglutarate-, and oxygen-dependent dioxygenases.
Dihydroxybenzoic acid and dimethyloxaloglycine are competitive inhibitors of 2-oxoglutarate, a cosubstrate in the HIF PHD catalytic cycle.
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ﬁndings are intriguing because it is well established that iron
chelators [74], ERK signaling pathway inhibitors [81,82], and
cycloheximide [83] can abrogate oxidative glutamate toxicity in
neurons. In the neuronal paradigm, glutamate, like erastin,
inhibits cystine uptake, leading to an iron-dependent, protein
synthesis-dependent form of cell death. And although it is as yet
unclear whether the genes necessary for erastin-induced ferrop-
tosis also are required for oxidative glutamate toxicity in neurons,
we have shown that an on-target effect of iron chelators in
preventing oxidative glutamate toxicity (probably a neuronal
form of ferroptosis) is the HIF prolyl hydroxylases [5], speciﬁcally
HIF prolyl hydroxylase 1 [84]. Thus we would argue that the
salutary effects of iron chelators in preventing ferroptosis can be
assigned to inhibition of a speciﬁc family of iron-, 2-oxoglutarate-,
and oxygen-dependent dioxygenases, the HIF prolyl hydroxylases,
and not to direct inhibition of Fenton chemistry or reactive oxygen
species formation.Cerebral ischemia
Epidemiology and pathology of cerebral ischemia
Stroke is a leading cause of death and long-term disability in
the United States [85]. Every year, about 795,000 people in the
United States have a stroke, and about 23% of people who survive
a stroke eventually have another [85]. In 2010, the estimated cost
of stroke in the United States was $53.9 billion, including the cost
of health care services, medications, and lost productivity [85].
Cerebral ischemia is the most common form of stroke, accounting
for approximately 87% of all strokes. Cerebral ischemia is deﬁned
as insufﬁcient blood ﬂow to the brain to supply an adequate
amount of oxygen and nutrients. Cerebral ischemia may result
from occlusion or constriction of blood vessels. At present, there is
only one FDA-approved drug treatment for cerebral ischemia: the
thrombolytic agent tissue plasminogen activator, which is recom-
mended for iv administration only within the ﬁrst 4.5 h after the
onset of stroke symptoms.
Unlike hypoxia, in which cells can maintain ATP levels by
shifting metabolism away from mitochondrial respiration and
toward glycolysis, ischemia involves a reduction in glucose
supply. Glucose is generally understood to be the obligatory
energy substrate for the brain; in an intact brain, astrocytes take
up glucose and utilize it for glycolysis and then shuttle pyruvate
and lactate into neurons, which then use these substrates for
oxidative phosphorylation [86]. More recently it has been shown
that ketone bodies can also be used by the brain as energy
substrates and, indeed, are taken up by the brain at an increased
rate during cerebral ischemia [87,88]. Nonetheless, in the
ischemic core where oxygen and glucose supplies are lowest,
ATP may be severely depleted within minutes; in a rat model of
forebrain ischemia, within 10 min glucose concentration dropped
from 3.64 to 0.21 mM/g and ATP concentration dropped from 2.64
to 0.18 mM/g, with corresponding increases in lactate and AMP
[89].
ATP depletion in the ischemic core causes rapid necrotic cell
death. Although many ATP-requiring processes such as gene
transcription, DNA repair, protein synthesis and trafﬁcking, and
proteasomal degradation can be shut down brieﬂy without
causing lasting harm, neurons need a constant supply of ATP to
maintain ionic gradients that support membrane polarization.
Loss of membrane potential leads to excessive glutamate release,
activation of extrasynaptic NMDA receptors, aberrant calcium
inﬂux, mitochondrial damage, and downstream intracellular sig-
naling events culminating in excitotoxic cell death (reviewed by[90]). In addition to glutamate-mediated mechanisms, a number
of other ion channels can contribute to ion dyshomeostasis and
activate cell death pathways, including sodium–calcium exchan-
gers, hemichannels, volume-regulated anion channels, acid-
sensing channels, transient receptor potential channels, and
nonselective cation channels [91]. Aberrant calcium inﬂux can
cause not only excitotoxic release of neurotransmitters but also
activation of calcium-dependent intracellular death pathways
(e.g., through calpain) and mitochondrial permeability transition
leading to caspase-dependent apoptotic cell death.
In the tissue surrounding a focal ischemic core, termed the
penumbra, collateral blood ﬂow produces gradients of oxygen and
glucose that allow cells to avoid rapid energetic crisis and necrotic
cell death, but many of these cells die in the 24–72 h after the
ischemic event. This death is largely apoptotic rather than
necrotic and follows a complex cascade of excitotoxicity, inﬂam-
mation, and oxidative stress [92]. Current strategies for develop-
ing novel therapeutics to reduce the loss of brain tissue and
motor/cognitive function are focused on restoring homeostasis
and promoting neuronal survival within the penumbral regions.
In experimental models of cerebral ischemia, hypoxic precondi-
tioning has been shown to be extremely effective in reducing
infarct volume and behavioral deﬁcits ([93]; reviewed by [94]).
Elucidating the mechanisms by which hypoxic preconditioning
affords protection has been a major focus of ischemia research.
Endogenous sensors of hypoxia and their downstream effectors of
broad, evolutionarily conserved adaptive responses to hypoxia are
prime targets for therapeutic manipulation [95]. Key among these
targets is the transcriptional activator HIF.
HIF-1a in cerebral ischemia
HIF-1a protein levels are increased in mouse and primate brains
after experimental cerebral ischemia [96,97], but it is unclear
whether HIF-1a limits or contributes to ischemic pathology.
In vivo models of cerebral ischemia show that HIF-1a can
prevent injury [98] and improve functional recovery [99] or
increase infarct and edema volume [100,101]. In a rat model of
focal ischemia, a biphasic induction of HIF-1a was observed both
in vivo and in vitro at 1–12 h after stroke and then again after
48 h, and selective inhibition of HIF-1a at the early but not the
late time point was neuroprotective [102]. In vitro models of
cerebral ischemia also show that HIF-1a either protects or
exacerbates cell death via expression of target genes that encode
both prosurvival and proapoptotic proteins [103,104] and demon-
strate divergent roles of HIF-1a in distinct CNS cell types [105].
Hypoxia and ischemia activate other stress response pathways
that engage in cross-talk with the HIF pathway, including endo-
plasmic reticulum (ER) stress-induced activation of the unfolded
protein response and suppression of protein synthesis [106].
Accumulation of misfolded proteins in the ER lumen leads to
PERK-mediated phosphorylation of eIF2a, inhibiting protein
synthesis to prevent further accumulation of unfolded proteins
in the ER. Therefore the rates of translation of HIF-1a, its target
genes, and its interactors are subject to additional layers of
regulation under hypoxic or ischemic conditions. In vitro studies
using oxygen and glucose deprivation have indicated that glucose
is required for hypoxic HIF-1a stabilization in human mesangial
and hepatoma (Hep3B) cells [107] and in human renal carcinoma
(UOK262) cells [108]. In considering how glucose deprivation
could curtail hypoxic HIF-1a stabilization, these researchers
considered that glucose not only supports ATP production
through glycolysis and mitochondrial oxidative phosphorylation,
but also supplies the pentose phosphate pathway (also known as
the hexose monophosphate shunt), which produces NADPH. They
proposed a model by which glucose fuels NADPH production
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shunt to provide a substrate for NADPH-dependent oxidases,
which in turn produce reactive oxygen species that inhibit prolyl
hydroxylases. According to this model, glucose deprivation
enhances HIF-1a degradation by relieving a ROS-mediated inhibition
of PHD enzyme activity. However, it remains unclear (1) whether
PHDs in fact mediate the effects of glucose and (2) whether this
model is applicable to neuronal cells. More recent work demonstrated
that NEDD8 conjugation to the PAS domain mediates ROS-
induced HIF stability, calling into question whether proline
hydroxylation is truly the target through which glucose depriva-
tion affects HIF-1a levels [109].Quantitative mechanistic reporters for HIF-1a as a surrogate
for dynamically monitoring PHD activity in cells
Although the potential therapeutic value of HIF PHD inhibition
and HIF-1a in cerebral ischemia has been widely appreciated for
over a decade, prior studies of HIF-1a regulation in neurons have
been limited by the difﬁculty of performing quantitative analysis
of immunoblotting employing commercially available HIF-1a
antibodies. This is particularly true in neuronal cells, in which
HIF-1a levels are very low, and complicates the study of post-
transcriptional modiﬁcations of HIF-1a that are key for under-
standing the mechanisms by which it is regulated. Further, given
the neuroprotective properties of prolyl hydroxylase inhibition,
a practical, quantitative reporter for PHD enzyme activity in vivo
would be extremely valuable. To address this gap, we have
developed a sensitive, speciﬁc reporter to quantitatively examine
distinct parts of the canonical HIF degradation pathway in human
neuronal cells, representing a substantial departure from the
status quo, namely the approach of looking only at HIF-1a levels
and HIF-1-mediated gene transcription [110].
HRE-promoter-driven luciferase reporters have been widely
used to measure HIF transactivation of target gene expression.
For example, HRE–luciferase expressed in an immortalized mouse
striatal neuron cell line, HT22, was used for high-throughput
screening of drugs that activate HIF-mediated transcription [111].
These constructs are valuable tools for assaying an endpoint of
HIF activation, but do not provide mechanistic insight regarding
HIF regulation. For measuring HIF-1a protein accumulation,
several reporters containing luciferase and green ﬂuorescent
protein (GFP) have been developed [112–114]. The main advan-
tage of using luciferase rather than GFP is the substantial increase
in sensitivity with an enzymatic assay; luciferase is 3 orders of
magnitude more sensitive and has a correspondingly much wider
dynamic range of linearity than ﬂuorescent proteins. Quantitative
assays of luciferase activity can be conﬁrmed with immunoblot-
ting with a highly speciﬁc and sensitive commercially available
monoclonal antibody against ﬁreﬂy luciferase that is much more
quantitative than currently available antibodies against HIF-1a.
A full-length HIF-1a reporter such as that used by Moroz et al.
[113], which includes the transactivation domain, introduces the
confound of exaggerating HIF-mediated gene transcription, thus
engaging feedback loops that may alter HIF-1a regulation. In
contrast, a reporter containing only the ODD domain lacks the
dimerization and DNA-binding domains, allowing it to report on
the oxygen-dependent regulation of HIF-1a protein levels with-
out interfering with endogenous HIF signaling. Some studies have
inferred PHD activity from HIF-1a levels without directly assaying
PHD enzyme activity [107,108]. This is problematic given that
HIF-1a protein stability is regulated in PHD-independent ways.
PHD enzymatic assays employing GST-fusion constructs have
been performed in cell lysates from HEK293 cells [115], but not
in neuronal cells. In vitro assays of PHD enzyme activity havebeen developed, but require large amounts of recombinant
enzyme and expensive reagents (reviewed by [116]). Therefore
it would be highly valuable to be able to biochemically detect not
only stabilization but prolyl hydroxylation and ubiquitination of a
HIF-1a reporter to identify mechanisms by which HIF-1a is
stabilized under given experimental conditions.
A fusion protein containing the oxygen-dependent degrada-
tion domain of HIF-1a (aa 530–652) fused to ﬁreﬂy luciferase
under control of the cytomegalovirus promoter has been pre-
viously used as a reporter for HIF-1a stabilization in high-
throughput screening for novel activators of the hypoxic response
[78] and for in vivo imaging [112,117]. These studies employing
the ODD–luc reporter have looked only at accumulation of the
reporter as measured by luciferase activity assay, without inves-
tigating the mechanism by which it accumulates or is degraded.
We have used the ODD–luc reporter as a quantitative reporter for
the oxygen-dependent degradation of HIF-1a in SH-SY5Y human
neuroblastoma cells, taking advantage of luciferase activity assays
and the wider dynamic range of luciferase antibodies relative to
antibodies for endogenous HIF-1a. We have conﬁrmed that ODD–
luc is regulated by PHD, VHL, and the proteasome in a manner
similar to that of endogenous HIF and found that ODD–luc is a
practical, speciﬁc, and quantitative reporter for the oxygen-
dependent degradation of HIF in human neuronal cells [110].
Further, immunoblotting for P564 hydroxylation on ODD–luc
provides a sensitive and quantitative direct assay of PHD enzyme
activity in human neuronal cells. We expect this reporter to
provide important information regarding PHD activity in vitro
and in vivo after ischemia (and in other neurological disorders)
and we expect that it will facilitate strategies to stabilize HIF in
ischemia. These efforts will provide additional, needed clariﬁca-
tion regarding the salutary and deleterious roles of HIF in
ischemia and how HIF PHD inhibition can be used to bias
outcomes favorably.Concluding remarks
In this review, we have tried to highlight the important
evolutionary role that hypoxic adaptation has played in metazo-
ans. We have reviewed the molecular mechanisms subserving
posttranscriptional and transcriptional adaptation to hypoxia,
focusing primarily on the nervous system. Finally, we highlight
the fact that HIF activation and HIF prolyl hydroxylase inhibition
are not interchangeable and the potential roles for inhibitors of
the HIF prolyl hydroxylases in a range of neurological conditions,
particularly stroke.Acknowledgments
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